Diabetic Nephropathy Type 2 Clinical Trial
— SGLT2i VS ACEiOfficial title:
Comparison Between the Efficacy of Sodium-Glucose Co-transporter 2 Inhibitor Therapy Versus Angiotensin-converting Enzyme Inhibitor in the Treatment of Diabetic Kidney Disease
Diabetes is the leading cause of chronic kidney disease (CKD) and end-stage kidney disease worldwide. Diabetic kidney disease (DKD) is a clinical diagnosis based upon the presence of reduced glomerular filtration rate (GFR) and/or increased urinary albumin excretion (UACR) in diabetes. The inhibition of the renin-angiotensin system (RAS) has been identified as the cornerstone in the management of DKD for decades. Recently, more evidence supports the use of Sodium-glucose cotransporter 2 inhibitors (SGLT2i) in the treatment of DKD. They were associated with slower progression of renal disease and lower rates of clinically relevant kidney events. Those studies confirmed the SGLT2i efficacy in kidney protection and showed that their addition to angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARBS) will be more effective than using ACEi or ARBS alone. It is unclear whether SGLT2i is used as a first-line instead of ACEi or ARB, and to what extent it will be effective in managing DKD compared to the proven effect of ACEi/ARBs alone. This study provides a unique opportunity to address this gap in the literature. The aim of this study is to compare, head to head, the renal performance of ACEi (standard of care) versus SGLT2 in diabetic patients who have evidence of deteriorating renal function evidenced by either the reduction of e GFR or increased UACR. Scientific hypotheses: Null hypothesis: after one year, the mean change of the e GFR in the enalapril group - Mean change of the e GFR in the empagliflozin group > or = 5 ml/min/1.73m2 Alternative hypothesis: after one year, the mean change of the e GFR in the enalapril group - Mean change of the e GFR in the empagliflozin group < 5 ml/min/1.73m2
Status | Not yet recruiting |
Enrollment | 212 |
Est. completion date | May 2024 |
Est. primary completion date | March 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 30 Years to 65 Years |
Eligibility | Inclusion Criteria: - Men& women with Type 2 Diabetic patient - Age 30-65 years old - UACR above 30mg/g - eGFR between 30-90 ml/min/1.73m2 - Signed and dated informed consent - Women must agree to use an effective birth control method if they are heterosexually active during the trial and should have a negative pregnancy test on day 1 Exclusion Criteria: - T1DM, History of diabetic ketoacidosis, beta-cell or pancreas transplantation, or diabetes secondary to pancreatitis or pancreatectomy - Age below 30 and above 65 years old - hyperkalemia (i.e., K above 6) - ESRF& e GFR less than 30 ml/min/1.73m2 - renal artery stenosis - type2 DM pregnant woman & gestational DM, breastfeeding - history of prior amputation or high risk for amputation (including severe peripheral vascular disease, neuropathy, and diabetic foot ulcers) - History of one or more severe hypoglycemic episodes within 6 months prior to screening Idiopathic or hereditary angioedema - allergies, or intolerance to trial medications or their excipients |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Omar Tarek Elfarargi |
Parving HH, Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S. [Effect of losartan on renal and cardiovascular complications of patients with type 2 diabetes and nephropathy]. Ugeskr Laeger. 2001 Oct 1;163(40):5514-9. Danish. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | blood pressure | measured in mmHg | One year | |
Other | the serum creatinine level | measured in mg/dL | one year | |
Other | the rates of clinical events (myocardial infarction, ESRD, congestive heart failure, and stroke) | if happened during the study | one year | |
Primary | estimated glomerular filtration rate | eGFR rate (determined by the Modification of Diet in Renal Disease [MDRD] equation) in ml/min/1.73m2 | one year | |
Secondary | the change in Urine Albumin Creatinine Ratio (UACR) | UACR (determined at first-morning void by at least 2 of 3 specimens obtained over a 3-to-6-month period) in mg/mmol | One year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03840343 -
Patient-Derived Stem Cell Therapy for Diabetic Kidney Disease
|
Phase 1 | |
Completed |
NCT04549324 -
Sleep Apnea, Coronary Atherosclerosis and Heart Failure in Diabetes Patients With Nephropathy
|
||
Recruiting |
NCT03502031 -
Safety and Efficacy of Two Year of RAAS Alone or in Combination With Spironolactone Therapy
|
Phase 4 | |
Completed |
NCT03681704 -
the Integrated Traditional Chinese and Western Medicine Treat Early Stage DKD
|
Phase 1 | |
Completed |
NCT03681249 -
the Integrated Traditional Chinese and Western Medicine Treat Middle Stage DKD
|
Early Phase 1 | |
Withdrawn |
NCT03504566 -
Rotation for Optimal Targeting of Albuminuria and Treatment Evaluation (ROTATE-2)
|
Phase 4 | |
Completed |
NCT03889236 -
Dietary Interventions on Glycocalyx Dimensions in South Asian Patients With Diabetic Nephropathy.
|
N/A | |
Completed |
NCT06326034 -
Impact of Dapagliflozin as Add-on Therapy on Glycemic Status and Quality of Life in Type 2 Diabetic Patients
|
Phase 4 | |
Recruiting |
NCT04931537 -
Screening and Application Research of Early Diabetic Nephropathy Markers Based on Lipidomics.
|
||
Recruiting |
NCT03622762 -
Green Tea Extract on Soluble RAGE in Patients With Diabetic Nephropathy
|
Phase 2 | |
Recruiting |
NCT03445247 -
Extracorporeal Low-intensity Shockwave in Diabetic Nephropathy
|
N/A | |
Not yet recruiting |
NCT06068439 -
Study of the Protective Effect of Low-dose Aspirin on Renal Function in Patients With Early Diabetic Nephropathy
|
Phase 2/Phase 3 | |
Recruiting |
NCT04143412 -
Efficacy of ACE Inhibitors, MRAs and ACE Inhibitor/ MRA Combination
|
Phase 2 | |
Not yet recruiting |
NCT06222476 -
Effect of Dorzagliatin on Renal Function Outcomes in People With Type 2 Diabetes: a Multicentric, Prospective, Randomized Study.
|
N/A | |
Completed |
NCT05487755 -
Investigational and Comparative Study in the Management of Diabetic Nephropathy
|
Phase 3 | |
Active, not recruiting |
NCT04573920 -
Atrasentan in Patients With Proteinuric Glomerular Diseases
|
Phase 2 | |
Recruiting |
NCT05888909 -
Multidimensional Accurate Diagnosis and Treatment Technology and Clinical Transformation of Type 2 Diabetes Nephropathy
|
||
Not yet recruiting |
NCT04962399 -
Relationship Between Serum N/OFQ and Type 2 Diabetic Nephropathy
|
||
Not yet recruiting |
NCT03591939 -
T-regulatory Cells in Diabetic Type Two Nephropathy
|
||
Active, not recruiting |
NCT03859817 -
Observational Study to Evaluate the Relationship Between Ketonemia and Renal Function in the Diabetic Patient
|